trending Market Intelligence /marketintelligence/en/news-insights/trending/UBiuSWb-j30HbjY3FtAgjA2 content esgSubNav
In This List

ObsEva sells rights to fertility drug that failed clinical trial

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


ObsEva sells rights to fertility drug that failed clinical trial

China's Hangzhou Yuyuan Bioscience Technology Co., Ltd. agreed to exclusively develop and commercialize ObsEva SA's fertility drug nolasiban in the country.

Switzerland-based ObsEva had previously decided to discontinue the development of nolasiban after the drug failed to increase the rate of pregnancy in a late-stage study when compared to placebo. The company has now decided to sublicense nolasiban to Yuyuan, which will fund the drug's clinical development, including two studies, in China.

The companies did not disclose the financial terms of the deal but noted instead that they would seek to expand their collaboration in China on other projects. Both companies also plan to collaborate on the global development of nolasiban, but Obseva will retain worldwide rights to the product outside of China.